Description

Product Description

Imsamotide (CAS 2130836-27-8), also known as IDO194-214, is a synthetic peptide derived from the enzyme Indoleamine 2,3-Dioxygenase (IDO). The peptide sequence, DTLLKALLEIASCLEKALQVF, represents amino acid residues 194–214 of IDO. This defined sequence has been identified as an immunologically relevant epitope and is currently under investigation for its ability to elicit immune responses in cancer and immunotherapy models.

IDO is a heme-containing enzyme responsible for the initial and rate-limiting step in tryptophan catabolism along the kynurenine pathway. Its activity has been linked to immunosuppressive tumor microenvironments, as elevated IDO expression in cancer cells contributes to immune evasion by depleting tryptophan and producing immunosuppressive metabolites. By targeting IDO-derived peptide fragments such as Imsamotide, researchers can study active immunization strategies aimed at breaking immune tolerance and restoring T-cell mediated anti-tumor responses.

As an immunological agent, Imsamotide offers a precise tool for studying peptide-based vaccines and T-cell epitope mapping. Preclinical studies indicate that Imsamotide can trigger IDO-specific cytotoxic T lymphocyte (CTL) activity, which may enhance anti-tumor immunity. The concept of employing IDO-derived epitopes as vaccine candidates represents a novel approach to immuno-oncology research.

Beyond its role as a peptide vaccine candidate, Imsamotide functions as an antineoplastic research agent, helping researchers explore how peptide-based immunization may synergize with checkpoint inhibitors, IDO enzymatic inhibitors, or other immunotherapies. The dual functionality makes it an attractive compound for studies in translational oncology.

Imsamotide is manufactured under GMP-certified conditions, ensuring ?98% purity, structural accuracy, and stability for reproducible experiments. It is supplied as a lyophilized white-to-off-white powder, stable for long-term storage at -20°C. Its high reproducibility makes it suitable for diverse applications, ranging from in vitro immunological assays to in vivo tumor models.

In summary, Imsamotide represents an innovative peptide-based research tool in the fields of immunology and oncology. By enabling the study of active immunization strategies and antineoplastic mechanisms, it contributes to advancing cancer immunotherapy research.

Product Specifications

Mechanism of Action & Research Applications

Imsamotide functions through epitope-specific activation of the adaptive immune system. As a synthetic peptide corresponding to a portion of the IDO enzyme, it serves as a tumor-associated antigen (TAA) in preclinical immunological research. When introduced in immunization models, Imsamotide can be presented by MHC class I or II molecules on antigen-presenting cells (APCs), leading to the activation of IDO-specific CD8+ and CD4+ T-cells.

Mechanistic Insights:

• Antigen Presentation: Processed Imsamotide peptides are presented via MHC pathways to prime T-cell responses.

• CTL Activation: Elicits cytotoxic T lymphocytes that target IDO-expressing tumor cells.

• Immune Modulation: Helps reverse tumor-induced immune tolerance by counteracting IDO-driven tryptophan catabolism.

• Synergy with Therapies: Enhances efficacy of immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) when combined.

Research Applications:

1. Cancer Immunotherapy Studies – Development of peptide vaccines targeting IDO-expressing tumors.

2. T-cell Epitope Mapping – Exploration of immune recognition of IDO-derived epitopes.

3. Combination Therapy Models – Synergistic studies with checkpoint inhibitors or IDO enzymatic inhibitors.

4. Immunological Mechanism Research – Understanding antigen processing, T-cell activation, and tolerance reversal.

5. Preclinical Oncology Models – Tumor regression studies in murine or translational models.

6. Peptide Vaccine Development – Proof-of-concept for therapeutic cancer vaccines.

Imsamotide thus enables exploration of tumor-immune interactions and provides a platform for advancing immunological research in oncology.

Side Effects (For Reference in Research Models)

Preclinical studies of IDO-derived peptide vaccines, including Imsamotide, report potential effects such as:

• Local Injection Site Reactions – Mild erythema, swelling, or irritation in animal models.

• Immune Overactivation – Potential for autoimmune-like responses in certain experimental designs.

• Cytokine Release – Alterations in IFN-?, TNF-?, and IL-2 levels in immunization studies.

• Off-target Immune Responses – Cross-reactivity risk with peptides of similar sequence motifs.

• Variable Efficacy – Response may differ across models depending on MHC haplotype.

• Adjuvant-Dependent Variability – Effects may differ when combined with immune adjuvants.

?? All observations are limited to laboratory models. Imsamotide is not approved for human or veterinary use.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Imsamotide

• Imsamotide CAS 2130836-27-8

• IDO194-214 peptide

• IDO-derived immunological peptide

• Antineoplastic research peptide

• GMP-grade immunization peptide

• Cancer vaccine peptide research

• Laboratory use IDO peptide

• T-cell epitope immunology peptide

• Immuno-oncology research tool